This is the guide I wish I had before starting in biotech IR. Most of the knowledge in this field is tacit — passed from senior to junior within firms. Here's what I learned at Solebury Trout working across biotech IPOs, follow-on offerings, and FDA-calendar events.
Why biotech IR is a different job than every other IR
In tech or industrial IR, your job is communicating financial performance and strategic direction. In biotech IR, the most important events are clinical trial readouts and FDA decisions — events that can move the stock 40% in a single day, often on data that most investors don't fully understand.
This creates a fundamentally different IR challenge: you're not just translating financial results — you're translating science into investment language, in real time, under extreme scrutiny from hedge funds who may be betting against you. The skill set is unique. And the compensation reflects it.
The FDA calendar and why it dominates biotech IR
Every biotech company with a drug in development is running against the FDA calendar. Key dates: PDUFA (Prescription Drug User Fee Act) dates are FDA decision deadlines for NDA/BLA applications. Advisory committee meetings happen before PDUFA dates for complex or novel drugs. Phase 2 and Phase 3 data readouts are the most volatile events.
Biotech IR is responsible for managing investor expectations around all of these events — including how much guidance to give before a readout, what data to share and when, and how to communicate outcomes regardless of whether they're positive or negative. Negative readouts require especially careful IR — how you communicate a trial failure determines whether investors stay or leave.
Managing IPOs and follow-on offerings in biotech
Biotech companies raise capital frequently — IPOs, S-1 filings, follow-on offerings, and ATM (at-the-market) programs. IR is deeply involved in all of these:
For an IPO: working with investment bankers on the roadshow deck and investor Q&A preparation, managing the order book alongside the banking team, supporting the CFO through the pricing process.
For follow-on offerings: determining the right timing based on the stock price, clinical calendar, and investor appetite; preparing the offering document; managing communications around the raise to minimize shareholder dilution concerns.
For ATM programs: IR monitors the stock performance and investor sentiment to inform the treasury team on when to draw on the ATM and at what size.
Crisis communications in biotech IR
Clinical failures are common in biotech. A Phase 3 failure for a lead asset can cut a company's market cap in half in a single trading session. Biotech IR has to be prepared for this.
Good crisis IR: get ahead of the news, communicate clearly and quickly, frame the path forward (remaining pipeline, cash runway, next catalyst), and be available to major shareholders immediately. The worst thing an IR team can do after bad news: go dark.
Activist investors add another layer. Biotech companies with failed programs, excess cash, or undervalued pipelines are frequent targets. IR plays a central role in managing activist situations — including developing the materials to defend the company's strategy and engaging with shareholders proactively before an activist goes public.
Who gets hired into biotech IR and how to position yourself
The ideal biotech IR candidate has some combination of: science background (biology, biochemistry, pre-med), finance or capital markets experience, and communications skills. In practice, firms hire from: sell-side biotech equity research (the most direct path), investment banking ECM or healthcare banking, medical or scientific communications, and IR consulting firms that specialize in life sciences (ICR, Stern IR, Solebury Trout).
For non-science backgrounds: the most important thing is demonstrating that you can learn and translate the science. Come into any interview having read the company's 10-K, recent clinical publications, and analyst reports on the pipeline. Know the phase of each program, the FDA pathway, and the key readout timeline. That preparation alone signals you can do the job.
Want biotech IR coaching from someone who's done it?
A session covers which biotech IR firms to target, how to position your background regardless of whether you have a science degree, and how to interview at a company where the pipeline is the whole conversation.
Book a Session